윤경호 교수 연구실
article|
인용수 11
·2025
Therapy for Atrial Fibrillation in Patients with Drug-Eluting Stents
Seung‐Jun Lee, Hee Tae Yu, Yong-Joon Lee, Sang‐Hyup Lee, Jung Ho Heo, Sung Gyun Ahn, Sanghoon Shin, Joon‐Hyung Doh, Ae‐Young Her, Byung Ryul Cho, Gwang-Sil Kim, Taek‐Geun Kwon, Sang Wook Lim, Jaemin Shim, Ji-Yong Jang, Kyounghoon Lee, Yun‐Hyeong Cho, Cheol Ung Choi, Sang Rok Lee, Hyung‐Bok Park, Han Cheol Lee, Seunghwan Kim, Kyeong Ho Yun, Jong Hwa Ahn, Byoung Kwon Lee, Deok‐Kyu Cho, Song‐Yi Kim, Ung Kim, Tae Soo Kang, Seong Huan Choi, Won–Ho Kim, Jin Bae Lee, Moo‐Yong Rhee, Jin‐Bae Kim, Sang‐Ho Jo, Dae Woo Hyun, Daehoon Kim, Tae-Hoon Kim, Sung‐Jin Hong, Jae‐Sun Uhm, Dong‐Ho Shin, Chul‐Min Ahn, Byeong‐Keuk Kim, Boyoung Joung, Young‐Guk Ko, Donghoon Choi, Myeong‐Ki Hong, Yangsoo Jang, Hui‐Nam Pak, Jung‐Sun Kim
New England Journal of Medicine
초록
Among patients with atrial fibrillation who had undergone implantation of a drug-eluting stent at least 1 year earlier, NOAC monotherapy was noninferior to combination therapy for net adverse clinical events. (Funded by Cardiovascular Research Center and Samjin Pharmaceutical; ADAPT AF-DES ClinicalTrials.gov number, NCT04250116.).
키워드
Atrial fibrillationAdverse effectStentCoronary artery diseaseClinical trial